



The Moran Foundation

DEPARTMENT OF PATHOLOGY
BAYLOR COLLEGE OF MEDICINE
TEXAS MEDICAL CENTER
HOUSTON, TEXAS 77030

June 23, 1992

Eugenio I. Banez, M.D.
Department of Pathology
Ben Taub General Hospital
1502 Taub Loop
Houston, TX 77030

Dear Dr. Banez:

Please update me on the status of your Moran Foundation project (2-91-0050) entitled "T Cell Activation During Myocardial Ischemia".

Since approval and funding is generally for a one-year period, all projects approved in or prior to June 1991 should now be "complete", or nearly so.

I need a progress and/or final report regarding your project, including dates and times of any presentations, and information regarding any publications.

Please submit this to me within the next 30 days.

Sincerely yours,

Philip J. Migliore, M.D.
Research Director

PJM/ms

c: Dr. Michael Lieberman
Mr. John Moran

Harris County Hospital District
Ben Taub General Hospital
Department of Pathology

July 24, 1992

Phillip J. Migliore, M.D.
Research Director
The Moran Foundation

Dear Dr. Migliore:

RE: T-cell Activation During Myocardial Infarction
2-92-50

We thank the Moran Foundation for giving us the opportunity to perform some very important preliminary studies in a most important clinical area, that of acute myocardial infarction (AMI). To our knowledge, this study represents the first attempt at investigating the immunologic responses in AMI with respect to T-cell activation. We have accomplished the following:

1. Defined the reference values for the expression of CD25 (Interleukin-2 receptor), CD71 (Transferrin receptor) and HLA-Dr (Ia) on normal T-lymphocytes. The reference population consisted of thirty blood donors in a defined state of health. It was important to define reference ranges for our laboratory because our initial studies showed that the control values were falling above published reference ranges. We found one published study confirming one of our observations - that the expression of CD25 on unstimulated lymphocytes is greater than what is generally accepted.
2. Studied, extensively, patients with AMI. CD25 showed the greatest progressive increase in expression within the first week of the acute episode. this was followed by Ia; CD71 expression is only mildly increased above the reference range.
3. Determined that with AMI, the $\alpha:\beta$ TCR+ T-cells are activated and the $\gamma:\delta$ TCR+ T-cells are not activated.

We plan to present our preliminary findings at a cardiology conference. When we shall have expanded the data to include more subjects, both control and test, we should be able to submit a paper for publication in a peer reviewed journal.

Sincerely yours,



Eugenio I. Bañez, M.D.
Principal Investigator
Moran Foundation Support 2-92-50
c:\infarctt\moran